{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:24:56Z","timestamp":1792887896379,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HD22C2045"],"award-info":[{"award-number":["HD22C2045"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This scoping review aimed to summarize the available studies to address the question of which therapeutic agents can be utilized for patients with post-acute sequelae of COVID-19 (PASC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a systematic search in medical databases, including PubMed and Embase, for studies aligned with our objectives published between January 1, 2020, and July 22, 2024. For each study, we summarized the main symptoms targeted, study design, therapeutic regimens, evaluation tools, and clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 413 studies were identified, and 39 studies were included in this review based on relevance to the research objectives. We primarily focused on high-level evidence studies, such as meta-analyses and randomized controlled trials, but observational studies were included when evidence was scarce. Therapeutic agents evaluated included hyperbaric oxygen, ivermectin, metformin, naltrexone, micronutrient supplements, antifibrotic agents, antiviral agents, and selective serotonin reuptake inhibitors (SSRIs). Among these, hyperbaric oxygen, antifibrotic agents, antiviral agents, and SSRIs demonstrated promising results. However, the heterogeneity of PASC symptoms posed challenges in synthesizing findings for specific symptom-based outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Given the heterogeneity of symptoms, this review highlights the need for standardized and targeted research to better address the diverse therapeutic needs of patients with PASC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-11131-x","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:22:45Z","timestamp":1747909365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review"],"prefix":"10.1186","volume":"25","author":[{"given":"Yu Bin","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"11131_CR1","unstructured":"World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. World Health Organization: 2021."},{"key":"11131_CR2","unstructured":"Centers for Disease Control and Prevention. Clinical overview of long COVID. 2024."},{"key":"11131_CR3","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2024."},{"key":"11131_CR4","unstructured":"Centers for Disease Control and Prevention, Long COVID. Household Pulse Survey. National Center for Health Statistics 2024."},{"key":"11131_CR5","unstructured":"Jang TI, Kim JY, Lim HS, Jeon SY, Choi H, Son KJ. Research report of National health insurance service Ilsan hospital: risk of clinical sequelae after the acute phase of SARS-CoV-2 infection. 2022."},{"key":"11131_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3947\/ic.2024.0024","volume":"56","author":"JW Seo","year":"2024","unstructured":"Seo JW, Kim SE, Kim Y, Kim EJ, Kim T, Kim T, et al. Updated clinical practice guidelines for the diagnosis and management of long COVID. Infect Chemother. 2024;56:122.","journal-title":"Infect Chemother"},{"key":"11131_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(21)00031-X","volume":"9","author":"P Venkatesan","year":"2021","unstructured":"Venkatesan P. NICE guideline on long COVID. Lancet Respiratory Med. 2021;9:129.","journal-title":"Lancet Respiratory Med"},{"key":"11131_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.cmi.2022.02.018","volume":"28","author":"D Yelin","year":"2022","unstructured":"Yelin D, Moschopoulos CD, Margalit I, Gkrania-Klotsas E, Landi F, Stahl JP, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022;28:955\u201372.","journal-title":"Clin Microbiol Infect"},{"key":"11131_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467\u201373.","journal-title":"Ann Intern Med"},{"key":"11131_CR10","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/biom11081210","volume":"11","author":"SD De Wolde","year":"2021","unstructured":"De Wolde SD, Hulskes RH, Weenink RP, Hollmann MW, Van Hulst RA. The effects of hyperbaric oxygenation on oxidative stress, inflammation and angiogenesis. Biomolecules. 2021;11:1210.","journal-title":"Biomolecules"},{"key":"11131_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/biom11101520","volume":"11","author":"I Gottfried","year":"2021","unstructured":"Gottfried I, Schottlender N, Ashery U. Hyperbaric oxygen Treatment-From mechanisms to cognitive improvement. Biomolecules. 2021;11:1520.","journal-title":"Biomolecules"},{"key":"11131_CR12","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/biom11121827","volume":"11","author":"N Schottlender","year":"2021","unstructured":"Schottlender N, Gottfried I, Ashery U. Hyperbaric oxygen treatment: effects on mitochondrial function and oxidative stress. Biomolecules. 2021;11:1827.","journal-title":"Biomolecules"},{"key":"11131_CR13","doi-asserted-by":"publisher","first-page":"11252","DOI":"10.1038\/s41598-022-15565-0","volume":"12","author":"S Zilberman-Itskovich","year":"2022","unstructured":"Zilberman-Itskovich S, Catalogna M, Sasson E, Elman-Shina K, Hadanny A, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12:11252.","journal-title":"Sci Rep"},{"key":"11131_CR14","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1038\/s41598-024-53091-3","volume":"14","author":"A Hadanny","year":"2024","unstructured":"Hadanny A, Zilberman-Itskovich S, Catalogna M, Elman-Shina K, Lang E, Finci S, et al. Long term outcomes of hyperbaric oxygen therapy in post Covid condition: longitudinal follow-up of a randomized controlled trial. Sci Rep. 2024;14:3604.","journal-title":"Sci Rep"},{"key":"11131_CR15","doi-asserted-by":"publisher","first-page":"103218","DOI":"10.1016\/j.nicl.2022.103218","volume":"36","author":"M Catalogna","year":"2022","unstructured":"Catalogna M, Sasson E, Hadanny A, Parag Y, Zilberman-Itskovich S, Efrati S. Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: A randomized, sham-controlled trial. NeuroImage: Clin. 2022;36:103218.","journal-title":"NeuroImage: Clin"},{"key":"11131_CR16","doi-asserted-by":"publisher","first-page":"9473","DOI":"10.1038\/s41598-023-36570-x","volume":"13","author":"M Leitman","year":"2023","unstructured":"Leitman M, Fuchs S, Tyomkin V, Hadanny A, Zilberman-Itskovich S, Efrati S. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial. Sci Rep. 2023;13:9473.","journal-title":"Sci Rep"},{"key":"11131_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12879-023-08002-8","volume":"23","author":"A Kjellberg","year":"2023","unstructured":"Kjellberg A, Hassler A, Bostrom E, El Gharbi S, Al-Ezerjawi S, Kowalski J, et al. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. BMC Infect Dis. 2023;23:33.","journal-title":"BMC Infect Dis"},{"key":"11131_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/2045-9912.310057","volume":"11","author":"S Sen","year":"2021","unstructured":"Sen S, Sen S. Therapeutic effects of hyperbaric oxygen: integrated review. Med Gas Res. 2021;11:30\u20133.","journal-title":"Med Gas Res"},{"key":"11131_CR19","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.","journal-title":"Antiviral Res"},{"key":"11131_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/cells8060559","volume":"8","author":"TM Tessier","year":"2019","unstructured":"Tessier TM, Dodge MJ, Prusinkiewicz MA, Mymryk JS. Viral appropriation: laying claim to host nuclear transport machinery. Cells. 2019;8:559.","journal-title":"Cells"},{"key":"11131_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","volume":"386","author":"G Reis","year":"2022","unstructured":"Reis G, Silva EA, Silva DC, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with Ivermectin among patients with Covid-19. N Engl J Med. 2022;386:1721\u201331.","journal-title":"N Engl J Med"},{"key":"11131_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1473-3099(23)00299-2","volume":"23","author":"CT Bramante","year":"2023","unstructured":"Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23:1119\u201329.","journal-title":"Lancet Infect Dis"},{"key":"11131_CR23","doi-asserted-by":"publisher","first-page":"106130","DOI":"10.1016\/j.jinf.2024.106130","volume":"88","author":"G Hayward","year":"2024","unstructured":"Hayward G, Yu L-M, Little P, Gbinigie O, Shanyinde M, Harris V, et al. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short-and longer-term outcomes. J Infect. 2024;88:106130.","journal-title":"J Infect"},{"key":"11131_CR24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","volume":"54","author":"H Xian","year":"2021","unstructured":"Xian H, Liu Y, Rundberg Nilsson A, Gatchalian R, Crother TR, Tourtellotte WG, et al. Metformin Inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54:1463\u201377.","journal-title":"Immunity"},{"key":"11131_CR25","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.3390\/ijms24076104","volume":"24","author":"IF Rosa","year":"2023","unstructured":"Rosa IF, Pecanha APB, Carvalho TRB, Alexandre LS, Ferreira VG, Doretto LB, et al. Photobiomodulation reduces the cytokine storm syndrome associated with COVID-19 in the zebrafish model. Int J Mol Sci. 2023;24:7104.","journal-title":"Int J Mol Sci"},{"key":"11131_CR26","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.lana.2021.100142","volume":"6","author":"G Reis","year":"2022","unstructured":"Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Cruz Milagres A, Ferreira TS, et al. Effect of early treatment with Metformin on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial. Lancet Reg Health - Americas. 2022;6:100142.","journal-title":"Lancet Reg Health - Americas"},{"key":"11131_CR27","first-page":"82","volume":"6","author":"K Toljan","year":"2018","unstructured":"Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of therapeutic utilization. Med Sci. 2018;6:82.","journal-title":"Med Sci"},{"key":"11131_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1186\/s12967-024-05412-3","volume":"22","author":"M Lohn","year":"2024","unstructured":"Lohn M, Wirth KJ. Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) and the therapeutic effect of low-dose Naltrexone. J Translational Med. 2024;22:630.","journal-title":"J Translational Med"},{"key":"11131_CR29","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.clinthera.2023.12.009","volume":"46","author":"L Tamariz","year":"2024","unstructured":"Tamariz L, Bast E, Klimas N, Palacio A. Low-dose Naltrexone improves post-COVID-19 condition symptoms. Clin Ther. 2024;46:e101. e106.\\.","journal-title":"Clin Ther"},{"key":"11131_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.adaj.2020.08.019","volume":"151","author":"E Hatfield","year":"2020","unstructured":"Hatfield E, Phillips K, Swidan S, Ashman L. Use of low-dose Naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc. 2020;151:891\u2013902.","journal-title":"J Am Dent Assoc"},{"key":"11131_CR31","first-page":"100733","volume-title":"Low-dose Naltrexone and NAD\u2009+\u2009for the treatment of patients with persistent fatigue symptoms after COVID-19","author":"A Isman","year":"2024","unstructured":"Isman A, Nyquist A, Strecker B, Harinath G, Lee V, Zhang X, et al. Low-dose Naltrexone and NAD\u2009+\u2009for the treatment of patients with persistent fatigue symptoms after COVID-19. Volume 36. Behavior, & Immunity - Health: Brain; 2024. p. 100733."},{"key":"11131_CR32","doi-asserted-by":"publisher","first-page":"215013192412586","DOI":"10.1177\/21501319241258671","volume":"15","author":"RT Hurt","year":"2024","unstructured":"Hurt RT, Yadav S, Schroeder DR, Croghan IT, Mueller MR, Grach SL, et al. Longitudinal progression of patients with long COVID treated in a Post-COVID clinic: A Cross-Sectional survey. J Prim Care Community Health. 2024;15:21501319241258671.","journal-title":"J Prim Care Community Health"},{"key":"11131_CR33","doi-asserted-by":"publisher","first-page":"110966","DOI":"10.1016\/j.intimp.2023.110966","volume":"124","author":"H Bonilla","year":"2023","unstructured":"Bonilla H, Tian L, Marconi VC, Shafer R, McComsey GA, Miglis M, et al. Low-dose Naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023;124:110966.","journal-title":"Int Immunopharmacol"},{"key":"11131_CR34","doi-asserted-by":"crossref","unstructured":"O\u2019Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain, Behavior, & Immunity - Health. 2022;24:100485.","DOI":"10.1016\/j.bbih.2022.100485"},{"key":"11131_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/ph14040336","volume":"14","author":"A Noce","year":"2021","unstructured":"Noce A, Albanese M, Marrone G, Di Lauro M, Pietroboni Zaitseva A, Palazzetti D, et al. Ultramicronized palmitoylethanolamide (um-PEA): a new possible adjuvant treatment in COVID-19 patients. Pharmaceuticals. 2021;14:336.","journal-title":"Pharmaceuticals"},{"key":"11131_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clinph.2022.10.017","volume":"145","author":"V Versace","year":"2023","unstructured":"Versace V, Ortelli P, Dezi S, Ferrazzoli D, Alibardi A, Bonini I, et al. Co-ultramicronized palmitoylethanolamide\/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome. Clin Neurophysiol. 2023;145:81\u20138.","journal-title":"Clin Neurophysiol"},{"key":"11131_CR37","first-page":"4156","volume":"25","author":"L D\u2019ascanio","year":"2021","unstructured":"D\u2019ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner M, Di Stadio A. Randomized clinical trial olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with palmitoylethanolamide and Luteolin: preliminary results. Eur Rev Med Pharmacol Sci. 2021;25:4156\u201362.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"11131_CR38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.2174\/1570159X20666220420113513","volume":"20","author":"A Di Stadio","year":"2022","unstructured":"Di Stadio A, D\u2019Ascanio L, Vaira LA, Cantone E, De Luca P, Cingolani C, et al. Ultramicronized palmitoylethanolamide and Luteolin supplement combined with olfactory training to treat post-COVID-19 olfactory impairment: a multi-center double-blinded randomized placebo-controlled clinical trial. Curr Neuropharmacol. 2022;20:2001\u201312.","journal-title":"Curr Neuropharmacol"},{"key":"11131_CR39","first-page":"8","volume":"1","author":"E Cantone","year":"2024","unstructured":"Cantone E, D\u2019Ascanio L, De Luca P, Roccamatisi D, La Mantia I, Brenner MJ, et al. Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics. Eur Arch Otorhinolaryngol. 2024;1:8.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"11131_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/brainsci14030293","volume":"14","author":"V Cenacchi","year":"2024","unstructured":"Cenacchi V, Furlanis G, Menichelli A, Lunardelli A, Pesavento V, Manganotti P. Co-ultraPEALut in subjective cognitive impairment following SARS-CoV-2 infection: an exploratory retrospective study. Brain Sci. 2024;14:293.","journal-title":"Brain Sci"},{"key":"11131_CR41","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.3390\/cells11162552","volume":"11","author":"P De Luca","year":"2022","unstructured":"De Luca P, Camaioni A, Marra P, Salzano G, Carriere G, Ricciardi L, et al. Effect of ultra-micronized palmitoylethanolamide and Luteolin on olfaction and memory in patients with long COVID: results of a longitudinal study. Cells. 2022;11:2552.","journal-title":"Cells"},{"key":"11131_CR42","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.3390\/nu15173701","volume":"15","author":"M Pirro","year":"2023","unstructured":"Pirro M, Ferri L, Piccioni L, Bellucci AM, Bartolucci F, Russo A, et al. What is the role of palmitoylethanolamide Co-Ultramicronized with Luteolin on the symptomatology reported by patients suffering from long COVID? A retrospective analysis performed by a group of general practitioners in a Real-Life setting. Nutrients. 2023;15:3701.","journal-title":"Nutrients"},{"key":"11131_CR43","first-page":"37","volume":"10","author":"L Raciti","year":"2022","unstructured":"Raciti L, De Luca R, Raciti G, Arcadi FA, Calabr\u00f2 RS. The use of palmitoylethanolamide in the treatment of long COVID: a real-life retrospective cohort study. Med Sci. 2022;10:37.","journal-title":"Med Sci"},{"key":"11131_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.nutr.21.1.167","volume":"21","author":"CB Stephensen","year":"2001","unstructured":"Stephensen CB. Vitamin A, infection, and immune function. Annu Rev Nutr. 2001;21:167\u201392.","journal-title":"Annu Rev Nutr"},{"key":"11131_CR45","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.3390\/nu5124836","volume":"5","author":"T Partearroyo","year":"2013","unstructured":"Partearroyo T, Ubeda N, Montero A, Achon M, Varela-Moreiras G. Vitamin B(12) and folic acid imbalance modifies NK cytotoxicity, lymphocytes B and lymphoprolipheration in aged rats. Nutrients. 2013;5:4836\u201348.","journal-title":"Nutrients"},{"key":"11131_CR46","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/nu12020292","volume":"12","author":"MG Kashiouris","year":"2020","unstructured":"Kashiouris MG, L\u2019Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler AA. The emerging role of vitamin C as a treatment for Sepsis. Nutrients. 2020;12:292.","journal-title":"Nutrients"},{"key":"11131_CR47","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11154-021-09679-5","volume":"23","author":"A Ismailova","year":"2022","unstructured":"Ismailova A, White JH. Vitamin D, infections and immunity. Reviews Endocr Metabolic Disorders. 2022;23:265\u201377.","journal-title":"Reviews Endocr Metabolic Disorders"},{"key":"11131_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.freeradbiomed.2014.03.035","volume":"72","author":"Q Jiang","year":"2014","unstructured":"Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med. 2014;72:76\u201390.","journal-title":"Free Radic Biol Med"},{"key":"11131_CR49","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.3390\/nu14234984","volume":"14","author":"M Tosato","year":"2022","unstructured":"Tosato M, Calvani R, Picca A, Ciciarello F, Galluzzo V, Coelho-Junior HJ, et al. Effects of l-Arginine plus vitamin C supplementation on physical performance, endothelial function, and persistent fatigue in adults with long COVID: A Single-Blind randomized controlled trial. Nutrients. 2022;14:4984.","journal-title":"Nutrients"},{"key":"11131_CR50","doi-asserted-by":"publisher","first-page":"101356","DOI":"10.1016\/j.bjorl.2023.101356","volume":"90","author":"LP Figueiredo","year":"2024","unstructured":"Figueiredo LP, Paim P, Cerqueira-Silva T, Barreto CC, Lessa MM. Alpha-lipoic acid does not improve olfactory training results in olfactory loss due to COVID-19: a double-blind randomized trial. Braz J Otorhinolaryngol. 2024;90:101356.","journal-title":"Braz J Otorhinolaryngol"},{"key":"11131_CR51","doi-asserted-by":"crossref","unstructured":"Sinopoli A, Sciurti A, Isonne C, Santoro MM, Baccolini Vl. The Efficacy of Multivitamin, Vitamin A, Vitamin B, Vitamin C. and Vitamin D Supplements in the Prevention and Management of COVID-19 and Long-COVID: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients. 2024;16:1345.","DOI":"10.3390\/nu16091345"},{"key":"11131_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5694\/mja2.50674","volume":"213","author":"PG Gibson","year":"2020","unstructured":"Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020;213:54\u20136. e51.","journal-title":"Med J Aust"},{"key":"11131_CR53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.medcle.2022.12.019","volume":"160","author":"B Kerget","year":"2023","unstructured":"Kerget B, Cil G, Araz O, Alper F, Akgun M. Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study. Med Clin (English Edition). 2023;160:525\u201330.","journal-title":"Med Clin (English Edition)"},{"key":"11131_CR54","first-page":"e29435","volume":"14","author":"R Choudhary","year":"2022","unstructured":"Choudhary R, Kumar A, Ali O, Pervez A. Effectiveness and safety of Pirfenidone and nintedanib for pulmonary fibrosis in COVID-19-Induced severe pneumonia: an interventional study. Cureus. 2022;14:e29435.","journal-title":"Cureus"},{"key":"11131_CR55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12890-024-02947-5","volume":"24","author":"HY Wang","year":"2024","unstructured":"Wang HY, Tsai SC, Lin YC, Hou JU, Chao CH. The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks. BMC Pulm Med. 2024;24:160.","journal-title":"BMC Pulm Med"},{"key":"11131_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/14782715221103402","volume":"52","author":"P Singh","year":"2022","unstructured":"Singh P, Behera D, Gupta S, Deep A, Priyadarshini S, Padhan P. Nintedanib vs Pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study. J Royal Coll Physicians Edinb. 2022;52:100\u20134.","journal-title":"J Royal Coll Physicians Edinb"},{"key":"11131_CR57","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/s41590-023-01601-2","volume":"24","author":"AD Proal","year":"2023","unstructured":"Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. 2023;24:1616\u201327.","journal-title":"Nat Immunol"},{"key":"11131_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133\u201346.","journal-title":"Nat Rev Microbiol"},{"key":"11131_CR59","doi-asserted-by":"crossref","unstructured":"Jiang J, Li Y, Jiang Q, Jiang Y, Qin H, Li Y. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis. J Infect. 2024;106190.","DOI":"10.1016\/j.jinf.2024.106190"},{"key":"11131_CR60","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.3390\/jcm12237375","volume":"12","author":"YJ Choi","year":"2023","unstructured":"Choi YJ, Seo YB, Seo JW, Lee J, Nham E, Seong H, et al. Effectiveness of antiviral therapy on long COVID: a systematic review and meta-analysis. J Clin Med. 2023;12:7375.","journal-title":"J Clin Med"},{"key":"11131_CR61","first-page":"865","volume":"114","author":"L Boglione","year":"2021","unstructured":"Boglione L, Meli G, Poletti F, Rostagno R, Moglia R, Cantone M, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does Remdesivir have a protective effect? QJM. Int J Med. 2021;114:865\u201371.","journal-title":"Int J Med"},{"key":"11131_CR62","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/v16060947","volume":"16","author":"C Fern\u00e1ndez-de-las-Pe\u00f1as","year":"2024","unstructured":"Fern\u00e1ndez-de-las-Pe\u00f1as C, Franco-Moreno A, Ruiz-Ruig\u00f3mez M, Arrieta-Ortubay E, Ryan-Murua P, Lumbreras-Bermejo C, et al. Is antiviral treatment with Remdesivir at the acute phase of SARS-CoV-2 infection effective for decreasing the risk of Long-Lasting Post-COVID symptoms?? Viruses. 2024;16:947.","journal-title":"Viruses"},{"key":"11131_CR63","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1038\/s41467-022-33825-5","volume":"13","author":"OP Nevalainen","year":"2022","unstructured":"Nevalainen OP, Horstia S, Laakkonen S, Rutanen J, Mustonen JM, Kalliala IE, et al. Effect of Remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022;13:6152.","journal-title":"Nat Commun"},{"key":"11131_CR64","doi-asserted-by":"publisher","first-page":"e28750","DOI":"10.1002\/jmv.28750","volume":"95","author":"MH Chuang","year":"2023","unstructured":"Chuang MH, Wu JY, Liu TH, Hsu WH, Tsai YW, Huang PY, et al. Efficacy of nirmatrelvir and Ritonavir for post-acute COVID\u201019 sequelae beyond 3 months of SARS\u2010CoV\u20102 infection. J Med Virol. 2023;95:e28750.","journal-title":"J Med Virol"},{"key":"11131_CR65","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamainternmed.2023.5099","volume":"183","author":"KW Fung","year":"2023","unstructured":"Fung KW, Baye F, Baik SH, McDonald CJ. Nirmatrelvir and molnupiravir and post\u2013COVID-19 condition in older patients. JAMA Intern Med. 2023;183:1404\u20136.","journal-title":"JAMA Intern Med"},{"key":"11131_CR66","doi-asserted-by":"crossref","unstructured":"Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381.","DOI":"10.1136\/bmj-2022-074572"},{"key":"11131_CR67","doi-asserted-by":"publisher","first-page":"e28992","DOI":"10.1002\/jmv.28992","volume":"95","author":"TH Liu","year":"2023","unstructured":"Liu TH, Chuang MH, Wu JY, Huang PY, Tsai YW, Hsu WH, et al. Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID\u201019: A multicenter matched cohort study. J Med Virol. 2023;95:e28992.","journal-title":"J Med Virol"},{"key":"11131_CR68","doi-asserted-by":"publisher","first-page":"e28951","DOI":"10.1002\/jmv.28951","volume":"95","author":"TH Liu","year":"2023","unstructured":"Liu TH, Wu JY, Huang PY, Tsai YW, Lai CC. The effect of nirmatrelvir-ritonavir on the long\u2010term risk of neuropsychiatric sequelae following COVID\u201019. J Med Virol. 2023;95:e28951.","journal-title":"J Med Virol"},{"key":"11131_CR69","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.7326\/M23-1394","volume":"176","author":"GN Ioannou","year":"2023","unstructured":"Ioannou GN, Berry K, Rajeevan N, Li Y, Mutalik P, Yan L, et al. Effectiveness of Nirmatrelvir\u2013Ritonavir against the development of Post\u2013COVID-19 conditions among US veterans: A target trial emulation. Ann Intern Med. 2023;176:1486\u201397.","journal-title":"Ann Intern Med"},{"key":"11131_CR70","doi-asserted-by":"crossref","unstructured":"Geng LN, Bonilla H, Hedlin H, Jacobson KB, Tian L, Jagannathan P et al. Nirmatrelvir-Ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial. JAMA Intern Med. 2024.","DOI":"10.1001\/jamainternmed.2024.2007"},{"key":"11131_CR71","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2147\/JIR.S456000","volume":"17","author":"GM Anderson","year":"2024","unstructured":"Anderson GM, Cook EH, Blakely RD, Sutcliffe JS, Veenstra-VanderWeele J. Long COVID-19 and peripheral serotonin: A commentary and reconsideration. J Inflamm Res. 2024;17:2169\u201372.","journal-title":"J Inflamm Res"},{"key":"11131_CR72","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12916-024-03655-x","volume":"22","author":"Z Butzin-Dozier","year":"2024","unstructured":"Butzin-Dozier Z, Ji Y, Deshpande S, Hurwitz E, Anzalone AJ, Coyle J, et al. SSRI use during acute COVID-19 and risk of long COVID among patients with depression. BMC Med. 2024;22:445.","journal-title":"BMC Med"},{"key":"11131_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.csbj.2023.12.045","volume":"24","author":"H Sidky","year":"2024","unstructured":"Sidky H, Hansen KA, Girvin AT, Hotaling N, Michael SG, Gersing K, et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Comput Struct Biotechnol J. 2024;24:115\u201325.","journal-title":"Comput Struct Biotechnol J"},{"key":"11131_CR74","doi-asserted-by":"publisher","first-page":"13462","DOI":"10.1038\/s41598-024-64260-9","volume":"14","author":"MI Prasanth","year":"2024","unstructured":"Prasanth MI, Wannigama DL, Reiersen AM, Thitilertdecha P, Prasansuklab A, Tencomnao T, et al. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications. Sci Rep. 2024;14:13462.","journal-title":"Sci Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:04:05Z","timestamp":1747911845000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11131"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11131-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"731"}}